Source: Newsmax

An Italian study found that hospitalized coronavirus patients who took anti-malaria drug hydroxychloroquine combined with azithromycin were 66% less likely to die.

Science Direct reports that the study also indicates a “larger effectiveness of hydroxychloroquine in patients with less severe COVID-19 disease.” 

The study involved 539 coronavirus patients who were hospitalized in Milan between Feb 24-May 17. Of those patients, the study noted that 174 died in the hospital. 

Some of the patients were divided into groups. One group of patients received hydroxychloroquine one day after they were admitted to the hospital. Another group received hydroxychloroquine and azithromycin. A third group received neither drug. The percent of death in the 3 groups was 27%, 23% and 51%, respectively, according to the study results. 

Mechanical ventilation was used in 4.3% of the patients who took hydroxychloroquine, 14.2% of patients who took both drugs and 26.1% of the control group of patients, the study reports. 

The study excluded people who were taking other medications that could have biased the effect of hydroxychloroquine.

Researchers write that they “question whether hydroxychloroquine should be further tested.”

They also state that additional studies should look into when it is best to start treatment. 

The use of the drug has been heavily debated. Some studies have shown the drug to be effective in treating the virus while others have halted studies after finding it is ineffective and can be dangerous and lead to cardiovascular issues. The Food and Drug Administration revoked its emergency use authorization for hydroxychloroquine on June 15. 




Related: France 24: Hydroxychloroquine effective in treating COVID-19, according to study of 2,500

Treatment with Hydroxychloroquine Cut Death Rate Significantly in COVID-19 Patients, Henry Ford Health System Study Shows

Zelenko study: COVID-19 Outpatients – Early Risk-Stratified Treatment with Zinc Plus Low Dose Hydroxychloroquine and Azithromycin; A Retrospective Case Series Study

Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/ azithromycin and other regimens in Marseille, France: A retrospective analysis

Share on facebook
Share on twitter
Share on whatsapp
On Trend

Latest Stories

A Conversation With Dr. Brian Tyson – The Chloroquine Wars Part XLI

The data from the vaccine trials must be recalculated under the lens that some of the serious adverse events (SAEs) should be treated as COVID-19 cases.
There may not be any vaccine efficacy in the data at all if some of the post-vaccination deaths are due to vaccine-induced COVID-19. It could even be the case that the mortality efficacy goes negative. My implied lives saved calculations put this easily in the realm of possibility. The only way to know is for authorities to organize and compile the data. And while a risk analysis is certainly due after more than six months of hundreds of millions of doses delivered, there is little indication authorities have bothered with the process. That’s more than a bit unsettling.

Read More »

Dr. Brian Tyson, USA: Hydroxychloroquine – Data, Strategies and Success Treating over 6000 Covid Patients

We continue to delve extensively into the COVID-19 data with esteemed statistician, Mathew Crawford. In this episode, we take a closer look at the use of early treatment and its success. Mathew has been researching the data from Dr. Brian Tyson, who has successfully treated over 6000 patients who contracted COVID throughout the pandemic. It is my great honor to have Dr. Tyson here on this episode to not only discuss the data, but also the strategies that he has been using throughout the pandemic.

Read More »